Mergers & Acquisitions In Brief
This article was originally published in The Gray Sheet
Executive Summary
China Medical divests ultrasound biz: China Medical Technologies divests its high-intensity focused ultrasound (HIFU) tumor therapy business to shareholder Chengxuan International for $53.5 million in order to refocus on in vitro diagnostics. Xiaodong Wu, who is both CEO of CMT and owner of Chengxuan, did not take part in deliberations over the sale, which was approved by CMT's independent board members, CMT notes. Announced Dec. 31, the move reflects pressures on the HIFU business from the global financial crisis, stricter regulations on medical equipment by China's State FDA, and the financial burden involved in obtaining U.S. and EU regulatory approvals for HIFU equipment, CMT explains. Beijing-based CMT recently acquired a human papillomavirus genotyping assay for $345 million, which it expects will generate up to $26.5 million in sales this year; the company will use the proceeds from the HIFU sale to further develop its molecular diagnostics business (1"The Gray Sheet" Oct. 13, 2008, p. 8)
You may also be interested in...
Medtronic Expands Renal Disease Focus With Bellco Buy
Medtronic has bought Bellco Health, adding the Italian company's hemodialysis products to its recently-formed Renal Care Solutions division.
J&J Will Extend Neuro Presence With $480 Million Micrus Acquisition
Johnson & Johnson's $480 million acquisition of Micrus Endovascular will expand its presence in the hemorrhagic stroke market and give the company a foothold in the high-promise ischemic stroke space
J&J Will Extend Neuro Presence With $480 Million Micrus Acquisition
Johnson & Johnson's $480 million acquisition of Micrus Endovascular will expand its presence in the hemorrhagic stroke market and give the company a foothold in the high-promise ischemic stroke space